Lorlatinib is a third-generation inhibitor, specifically targeting ALK and ROS1 kinases, It’s for treating ALK-positive lung cancer that has spread and didn’t get better with other ALK inhibitors. You can get it as tablets, either 25 mg or 100 mg ones.
You usually take 100 mg of it once a day, whether with or without food. Each bottle holds 30 of the 100 mg tablets.
